T1	Participants 44 67	migraine in adolescents
T2	Participants 286 314	Patients aged 12 to 17 years
T3	Participants 315 371	received rizatriptan 5 mg (n = 149) or placebo (n = 147)
#1	AnnotatorNotes T3	2 groups under trial
